KR102352022B1 - Pge2 수용체 조절제로서의 n-치환된 인돌 유도체 - Google Patents

Pge2 수용체 조절제로서의 n-치환된 인돌 유도체 Download PDF

Info

Publication number
KR102352022B1
KR102352022B1 KR1020187017474A KR20187017474A KR102352022B1 KR 102352022 B1 KR102352022 B1 KR 102352022B1 KR 1020187017474 A KR1020187017474 A KR 1020187017474A KR 20187017474 A KR20187017474 A KR 20187017474A KR 102352022 B1 KR102352022 B1 KR 102352022B1
Authority
KR
South Korea
Prior art keywords
pyrimidin
indol
fluoro
methoxy
ethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187017474A
Other languages
English (en)
Korean (ko)
Other versions
KR20180081810A (ko
Inventor
하인츠 프레츠
이사벨 료띠에
줄리앙 포띠에
실비아 리샤르-빌드스뜨앵
티에리 시페르랑
페터스 로렌차 비더
다비데 포치
올리비에 꼬르망뵈프
Original Assignee
이도르시아 파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이도르시아 파마슈티컬스 리미티드 filed Critical 이도르시아 파마슈티컬스 리미티드
Publication of KR20180081810A publication Critical patent/KR20180081810A/ko
Application granted granted Critical
Publication of KR102352022B1 publication Critical patent/KR102352022B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187017474A 2015-11-20 2016-11-17 Pge2 수용체 조절제로서의 n-치환된 인돌 유도체 Active KR102352022B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2015/077269 2015-11-20
EP2015077269 2015-11-20
PCT/EP2016/078028 WO2017085198A1 (en) 2015-11-20 2016-11-17 N-substituted indole derivatives as pge2 receptor modulators

Publications (2)

Publication Number Publication Date
KR20180081810A KR20180081810A (ko) 2018-07-17
KR102352022B1 true KR102352022B1 (ko) 2022-01-14

Family

ID=57326428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017474A Active KR102352022B1 (ko) 2015-11-20 2016-11-17 Pge2 수용체 조절제로서의 n-치환된 인돌 유도체

Country Status (34)

Country Link
US (2) US11241431B2 (enExample)
EP (2) EP3928836B1 (enExample)
JP (2) JP2018534328A (enExample)
KR (1) KR102352022B1 (enExample)
CN (1) CN108349949B (enExample)
AU (1) AU2016358242B2 (enExample)
BR (1) BR112018010291B1 (enExample)
CA (1) CA3002610C (enExample)
CL (1) CL2018001325A1 (enExample)
CO (1) CO2018005715A2 (enExample)
CR (1) CR20180323A (enExample)
CY (1) CY1124913T1 (enExample)
DK (2) DK3377483T3 (enExample)
EA (1) EA037953B1 (enExample)
ES (2) ES2994636T3 (enExample)
FI (1) FI3928836T3 (enExample)
HR (2) HRP20211678T1 (enExample)
HU (2) HUE069520T2 (enExample)
IL (1) IL259424B (enExample)
LT (2) LT3928836T (enExample)
MA (2) MA43251B1 (enExample)
MX (1) MX375978B (enExample)
MY (1) MY195888A (enExample)
PE (1) PE20181304A1 (enExample)
PH (1) PH12018501077B1 (enExample)
PL (2) PL3377483T3 (enExample)
PT (2) PT3377483T (enExample)
RS (2) RS62598B1 (enExample)
SA (1) SA518391588B1 (enExample)
SG (1) SG11201803627XA (enExample)
SI (2) SI3928836T1 (enExample)
TW (2) TWI719078B (enExample)
UA (1) UA123441C2 (enExample)
WO (1) WO2017085198A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
JP7330894B2 (ja) 2017-03-27 2023-08-22 ハイドロ－ケベック 電解質組成物中でまたは電極の添加剤として使用される塩
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
HRP20211380T1 (hr) 2017-05-18 2021-11-26 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
CN109678780A (zh) * 2017-10-19 2019-04-26 中国石油化工股份有限公司 一种制备3-烷基吲哚衍生物的方法
AU2018368790A1 (en) 2017-11-20 2020-06-25 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
AU2019205944A1 (en) 2018-01-05 2020-07-09 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
EP3768267B1 (en) 2018-03-20 2025-05-14 Icahn School of Medicine at Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
AU2019418800A1 (en) * 2018-12-31 2021-07-01 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3693359A1 (en) * 2019-02-08 2020-08-12 Medibiofarma, S.L. New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療
EP4359399A4 (en) 2021-06-24 2025-04-23 Reservoir Neuroscience, Inc. EP2 antagonist compounds
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006583A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
WO2008152093A2 (en) 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidines as modulators of the ep2 receptor
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
WO2014044755A1 (en) 2012-09-21 2014-03-27 Chemilia Ab 4-(indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
JP2003528144A (ja) 2000-03-24 2003-09-24 ファーマジーン ラボラトリーズ リミテッド 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
BR0309305A (pt) 2002-04-12 2005-02-15 Pfizer Compostos de imidazol como agentes antiinflamatórios e analgésicos
JP2006506327A (ja) 2002-05-23 2006-02-23 セラテクノロジーズ インコーポレイティド プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
CA2514220C (en) 2003-01-29 2012-02-28 Pharmagene Laboratories Limited Ep4 receptor antagonists
AR045507A1 (es) 2003-08-26 2005-11-02 Teijin Pharma Ltd Derivados de pirrolo [3,2-d] pirimidina
ES2441206T3 (es) 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7326732B2 (en) * 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
ES2327760T3 (es) 2004-05-04 2009-11-03 Raqualia Pharma Inc Compuestos de aril-heteroaril-amida ortosustituidos.
WO2005105732A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
EP1885722B1 (en) 2005-05-19 2011-11-16 Merck Canada Inc. Quinoline derivatives as ep4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AR060403A1 (es) 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
WO2008017164A1 (en) 2006-08-11 2008-02-14 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
US8030489B2 (en) 2007-03-26 2011-10-04 Astellas Pharma Inc. Ornithine derivative
CN101636385B (zh) 2007-03-26 2012-09-05 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
KR20100090772A (ko) 2007-10-12 2010-08-17 인게니움 파르마코이티칼스 게엠베하 단백질 키나제 억제제
CA2714743C (en) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
KR101612971B1 (ko) 2008-05-14 2016-04-15 아스테라스 세이야쿠 가부시키가이샤 아미드 화합물
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
CA2733247C (en) 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010032123A1 (en) 2008-09-19 2010-03-25 Biotechnology Research Corporation Limited Triterpenoid compounds and methods of use thereof
AU2009295308A1 (en) 2008-09-25 2010-04-01 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
AU2010321905A1 (en) 2009-11-23 2012-05-24 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
LT2619182T (lt) 2010-09-21 2017-01-25 Eisai R&D Management Co., Ltd. Farmacinė kompozicija
WO2012043634A1 (ja) 2010-09-29 2012-04-05 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
AU2011331161A1 (en) 2010-11-17 2013-05-02 Novartis Ag 3-(aminoaryl)-pyridine compounds
EP2649061B1 (en) 2010-12-10 2015-05-13 Rottapharm Biotech S.r.l. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
WO2012149528A1 (en) 2011-04-29 2012-11-01 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
CA2839956A1 (en) 2011-06-20 2012-12-27 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
KR101760164B1 (ko) 2011-07-04 2017-07-20 로타팜 바이오테크 에스.알.엘 Ep4 수용체 길항제로서 사이클릭 아민 유도체
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
IN2014KN02601A (enExample) 2012-04-24 2015-05-08 Vertex Pharma
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
BR112015011497B1 (pt) 2012-11-27 2023-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Composto, e, formulação farmacêutica
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
RS57406B1 (sr) 2013-06-12 2018-09-28 Kaken Pharmaceutical Co Ltd Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物
EA030155B1 (ru) 2013-09-06 2018-06-29 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,2,4-оксадиазола в качестве иммуномодуляторов
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
RS57306B1 (sr) 2013-10-17 2018-08-31 Vertex Pharma Inhibitori dnk-pk
PL3424920T3 (pl) 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
WO2015094902A1 (en) 2013-12-17 2015-06-25 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
HRP20190793T1 (hr) 2013-12-17 2019-06-28 Eli Lilly & Company Spojevi dimetilbenzojeve kiseline
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
EP3137074B1 (en) 2014-04-29 2020-08-05 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
SG11201609770TA (en) 2014-05-23 2016-12-29 Eisai R&D Man Co Ltd Combination therapies for the treatment of cancer
EP3151833A4 (en) 2014-06-04 2018-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
TWI852872B (zh) 2015-01-09 2024-08-11 日商小野藥品工業股份有限公司 三環性螺化合物之用途
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
AU2016338679B2 (en) 2015-10-16 2021-05-06 Eisai R&D Management Co., Ltd. EP4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
MA45670A (fr) 2016-07-13 2019-05-22 Vertex Pharma Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
HRP20211380T1 (hr) 2017-05-18 2021-11-26 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
SI3625224T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-substituirani indolni derivati
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006583A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
WO2008152093A2 (en) 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidines as modulators of the ep2 receptor
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
WO2014044755A1 (en) 2012-09-21 2014-03-27 Chemilia Ab 4-(indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer

Also Published As

Publication number Publication date
PH12018501077A1 (en) 2019-01-28
JP2021107417A (ja) 2021-07-29
CL2018001325A1 (es) 2018-08-10
MA55046A (fr) 2021-12-29
DK3928836T3 (da) 2024-10-14
MX2018005268A (es) 2018-11-29
EP3377483A1 (en) 2018-09-26
AU2016358242A1 (en) 2018-07-05
EA201891179A1 (ru) 2018-11-30
DK3377483T3 (da) 2021-12-06
PH12018501077B1 (en) 2019-01-28
US11241431B2 (en) 2022-02-08
PE20181304A1 (es) 2018-08-09
LT3377483T (lt) 2021-11-10
UA123441C2 (uk) 2021-04-07
RS66179B1 (sr) 2024-12-31
US20200289507A1 (en) 2020-09-17
SI3928836T1 (sl) 2025-03-31
HRP20241521T1 (hr) 2025-01-03
SI3377483T1 (sl) 2022-01-31
KR20180081810A (ko) 2018-07-17
CN108349949B (zh) 2020-11-17
SA518391588B1 (ar) 2021-03-17
PT3928836T (pt) 2024-11-29
CO2018005715A2 (es) 2018-07-10
TW202120497A (zh) 2021-06-01
EP3928836A1 (en) 2021-12-29
EP3377483B1 (en) 2021-09-01
WO2017085198A1 (en) 2017-05-26
TWI719078B (zh) 2021-02-21
MA55046B1 (fr) 2024-10-31
US20220175775A1 (en) 2022-06-09
TW201726661A (zh) 2017-08-01
CY1124913T1 (el) 2023-01-05
BR112018010291B1 (pt) 2023-12-26
BR112018010291A2 (pt) 2018-11-06
ES2897954T3 (es) 2022-03-03
MA43251B1 (fr) 2021-11-30
RS62598B1 (sr) 2021-12-31
MX375978B (es) 2025-03-07
HRP20211678T1 (hr) 2022-03-04
EP3377483B9 (en) 2022-08-03
US12011444B2 (en) 2024-06-18
ES2994636T3 (en) 2025-01-28
CR20180323A (es) 2018-08-06
PL3928836T3 (pl) 2025-01-07
FI3928836T3 (fi) 2024-11-08
TWI754397B (zh) 2022-02-01
PT3377483T (pt) 2021-11-22
LT3928836T (lt) 2024-12-27
AU2016358242B2 (en) 2021-03-11
IL259424B (en) 2020-11-30
JP2018534328A (ja) 2018-11-22
JP7228618B2 (ja) 2023-02-24
CN108349949A (zh) 2018-07-31
MY195888A (en) 2023-02-27
HUE069520T2 (hu) 2025-03-28
CA3002610A1 (en) 2017-05-26
CA3002610C (en) 2022-03-15
PL3377483T3 (pl) 2022-01-31
SG11201803627XA (en) 2018-06-28
MA43251A (fr) 2021-04-28
HUE056679T2 (hu) 2022-02-28
IL259424A (en) 2018-07-31
EA037953B1 (ru) 2021-06-11
EP3928836B1 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
US12011444B2 (en) N-substituted indole derivatives as PGE2 receptor modulators
KR102612649B1 (ko) Pge2 수용체 조절제로서의 벤조푸란 및 벤조티오페논 유도체
KR102612140B1 (ko) 피리미딘 유도체
KR102632028B1 (ko) Pge2 수용체 조절제로서의 페닐 유도체
HK40065654A (en) N-substituted indole derivatives as pge2 receptor modulators

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5